CSTL
Castle Biosciences, Inc.
NasdaqGMUSDEQUITY
Healthcare
DELAYED
Last price
34.20
▲ 1.27 (3.86%)
MARKET · —
Price
Open
32.97
Prev close
32.93
Day high
34.70
Day low
32.14
Volume
573.47K
Market cap
$1.04B
P/E (TTM)
—
52W range
17.72 – 44.28
Trailing performance
Returnvs SPY
1W
+15.46%
+16.8%
1M
+34.22%
+30.5%
3M
+66.50%
+63.4%
6M
+17.08%
+6.0%
YTD
-12.08%
-24.4%
1Y
+72.90%
+52.9%
3Y
+88.43%
+14.3%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Fundamentals
Market cap$1.04B
Enterprise value$814.64M
Revenue (TTM)$357.28M
Gross profit$276.03M
EBITDA$-16.52M
Net income$-19.41M
EPS (TTM)$-0.64
Free cash flow$-7.26M
Total cash$266.80M
Total debt$36.65M
Book value / share$15.41
Shares outstanding30.55M
Float27.09M
Short % of float5.24%
Dividend yield—
Beta (5Y)0.97
Valuation & profitability ratios
Trailing P/E—
Forward P/E-34.58
PEG ratio—
Price / sales—
Price / book2.22
EV / revenue2.28
EV / EBITDA-49.32
Gross margin77.26%
Operating margin-2.96%
Profit margin-5.43%
Return on equity-4.20%
Return on assets-1.36%
Debt / equity7.80
Current ratio6.04
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Total revenue | $344.23M | $332.07M | $219.79M | $137.04M |
| Cost of revenue | $0 | $0 | $0 | $0 |
| Gross profit | $0 | $0 | $0 | $0 |
| R&D | — | — | — | — |
| SG&A | — | — | — | — |
| Operating income | — | — | — | — |
| Pre-tax income | — | — | — | — |
| Tax provision | $0 | $0 | $0 | $0 |
| Net income | -$24.16M | $18.25M | -$57.47M | -$67.14M |
| EBIT | $0 | $0 | $0 | $0 |
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Cash & equivalents | — | — | — | — |
| Short-term investments | — | — | — | — |
| Net receivables | — | — | — | — |
| Inventory | — | — | — | — |
| Total current assets | — | — | — | — |
| Total assets | — | — | — | — |
| Total current liabilities | — | — | — | — |
| Long-term debt | — | — | — | — |
| Total liabilities | — | — | — | — |
| Retained earnings | — | — | — | — |
| Shareholder equity | — | — | — | — |
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Net income | -$24.16M | $18.25M | -$57.47M | -$67.14M |
| Depreciation | — | — | — | — |
| Change in working capital | — | — | — | — |
| Operating cash flow | — | — | — | — |
| Capital expenditure | — | — | — | — |
| Investing cash flow | — | — | — | — |
| Dividends paid | — | — | — | — |
| Buybacks | — | — | — | — |
| Financing cash flow | — | — | — | — |
| Net change in cash | — | — | — | — |
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.41 | -0.07 | +82.8% |
| Mar 2026 | -0.49 | -0.49 | -0.3% |
| Dec 2025 | -0.26 | -0.08 | +69.1% |
| Sep 2025 | -0.51 | -0.02 | +96.1% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.36 | 9 | $92.21M | +11.0% |
| Next quarter | -0.36 | 9 | $93.85M | +7.9% |
| Current year | -1.27 | 9 | $372.90M | +8.3% |
| Next year | -0.99 | 9 | $409.43M | +9.8% |
Analyst targets & ownership
Mean target$44.00
High target$57.00
Low target$35.00
Implied upside28.65%
Analyst count9
ConsensusSTRONG BUY
Strong buy / Buy0 / 9
Hold0
Sell / Strong sell0 / 0
Held by insiders2.48%
Held by institutions90.85%
Institutions holding259
Price targets, consensus spread, insider and institutional ownership.
Insider net activity
Net shares
-16.41K
Net selling
Buy transactions
28
336.73K shares
Sell transactions
27
353.14K shares
Net transactions
+55
Buys less sells
Sell : buy shares
1.0 : 1
Mixed
Insider-held shares
756.10K
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Aug 17, 26 | JUVENAL TOBIN W Officer |
SELL | 1.73K | $51.19K | Direct |
| Aug 14, 26 | MAETZOLD DEREK J Chief Executive Officer |
CONVERSION | 1.10K | $2.63K | Direct |
| Aug 14, 26 | STOKES FRANKLIN M. Chief Financial Officer |
SELL | 24.91K | $741.51K | Direct |
| Aug 14, 26 | MAETZOLD DEREK J Chief Executive Officer |
SELL | 7.23K | $217.10K | |
| Aug 5, 26 | MAETZOLD DEREK J Chief Executive Officer |
CONVERSION | 22.90K | $54.74K | Direct |
| Aug 5, 26 | MAETZOLD DEREK J Chief Executive Officer |
SELL | 39.02K | $1.21M | |
| Aug 3, 26 | MAETZOLD DEREK J Chief Executive Officer |
CONVERSION | 17.14K | $40.97K | Direct |
| Aug 3, 26 | OELSCHLAGER KRISTEN M Chief Operating Officer |
SELL | 8.59K | $255.62K | Direct |
| Aug 3, 26 | JUVENAL TOBIN W Officer |
SELL | 19.04K | $556.17K | Direct |
| Aug 3, 26 | MAETZOLD DEREK J Chief Executive Officer |
SELL | 28.65K | $867.45K | |
| Jul 27, 26 | MAETZOLD DEREK J Chief Executive Officer |
CONVERSION | 6.21K | $14.85K | Direct |
| Jul 27, 26 | MAETZOLD DEREK J Chief Executive Officer |
SELL | 9.84K | $237.68K | |
| Jul 14, 26 | MAETZOLD DEREK J Chief Executive Officer |
CONVERSION | 550 | $1.31K | Direct |
| Jul 14, 26 | MAETZOLD DEREK J Chief Executive Officer |
SELL | 4.17K | $95.62K |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
BRADBURY DANIEL M |
Director | 35.63K | Conversion of Exercise of derivative security |
CAPLE KIM |
Director | 36.12K | Conversion of Exercise of derivative security |
COTTON RODNEY |
Director | 33.00K | Conversion of Exercise of derivative security |
GOLDBERG ELLEN |
Director | 40.92K | Conversion of Exercise of derivative security |
HARRISON MILES D |
Director | 35.63K | Conversion of Exercise of derivative security |
JUVENAL TOBIN W |
Officer | 75.96K | Sale |
MAETZOLD DEREK J |
Chief Executive Officer | 209.25K | Conversion of Exercise of derivative security |
OELSCHLAGER KRISTEN M |
Chief Operating Officer | 110.54K | Sale |
OLSON TIFFANY |
Director | 39.57K | Conversion of Exercise of derivative security |
STOKES FRANKLIN M. |
Chief Financial Officer | 35.18K | Sale |
Moving averages & technicals
SMA 10
31.46
+8.70% from price
SMA 20
29.83
+14.64% from price
SMA 50
25.83
+32.39% from price
SMA 100
24.13
+41.74% from price
SMA 200
29.43
+16.20% from price
EMA 12
31.15
+9.81% from price
EMA 26
29.18
+17.22% from price
EMA 50
27.16
+25.93% from price
RSI (14)
71.4
Overbought
MACD (12,26,9)
1.97
Hist 0.11
ATR (14)
1.76
5.14% of price
Realised vol 30D
57.7%
Annualised
Bollinger upper
35.57
20, 2σ
Bollinger lower
24.10
20, 2σ
50 / 200 cross
Death
25.83 vs 29.43
Trend bias
Above 200
+16.20%
Risk profile
Beta vs SPY
0.93
Less volatile than market
Correlation to SPY
0.21
Largely independent
Realised vol 30D
57.7%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-57.8%
Peak to trough
Max drawdown 5Y
-85.0%
Peak to trough
ATR 14
1.76
5.14% of price
Beta (reported)
0.97
5Y monthly, from filing
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Options analytics
Put / call volume
0.22
Call-heavy session
Put / call open interest
0.56
Positioning, not flow
Max pain
25.00
-26.9% from spot
ATM implied vol
55.7%
Nearest strike to spot
Skew (10% OTM)
+17.1%
Puts bid over calls
Call volume
9
Contracts, this expiry
Put volume
2
Contracts, this expiry
Heaviest call OI
35.00
4 contracts
Heaviest put OI
25.00
4 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Headlines
Castle Biosciences to Participate in Upcoming Investor Conferences
PR Newswire · 2d ago
Castle Biosciences Approved for Dual Listing on Nasdaq Texas
PR Newswire · 5d ago
Castle Biosciences Raises Outlook as Melanoma, TissueCypher Tests Gain Traction
MarketBeat · 9d ago
Castle Biosciences, Inc. Q2 2026 Earnings Call Summary
Moby · 22d ago
Castle Biosciences Inc (CSTL) (Q2 2026) Earnings Call Highlights: Revenue Surges 20% to $103. ...
GuruFocus.com · 22d ago
Castle Biosciences Q2 Earnings Call Highlights
MarketBeat · 23d ago
Castle Biosciences, Inc. (CSTL) Reports Q2 Loss, Tops Revenue Estimates
Zacks · 23d ago
Castle Biosciences Reports Second Quarter 2026 Results
PR Newswire · 23d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.